Vident Advisory LLC Cuts Stake in Boston Scientific Corporation $BSX

Key Points

• Vident Advisory LLC reduced its holdings in Boston Scientific Corporation by 15.1% during the 1st quarter, ending with 86,518 shares valued at about $8.73 million.
• Boston Scientific reported a 22.8% year-over-year revenue increase, reaching $5.06 billion for the quarter, significantly exceeding analyst expectations.
• Multiple hedge funds, including Vanguard and Goldman Sachs, increased their positions in Boston Scientific, highlighting strong institutional interest in the company, with 89.07% of the stock owned by institutional investors.

Vident Advisory LLC lessened its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 15.1% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 86,518 shares of the medical equipment provider's stock after selling 15,387 shares during the period. Vident Advisory LLC's holdings in Boston Scientific were worth $8,728,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in BSX. Brighton Jones LLC lifted its stake in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after acquiring an additional 226 shares during the period. Bank Pictet & Cie Europe AG increased its stake in Boston Scientific by 40.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after buying an additional 21,173 shares during the period. Highview Capital Management LLC DE increased its stake in Boston Scientific by 6.2% in the 4th quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock valued at $2,189,000 after buying an additional 1,439 shares during the period. Rehmann Capital Advisory Group increased its stake in Boston Scientific by 6.9% in the 4th quarter. Rehmann Capital Advisory Group now owns 5,245 shares of the medical equipment provider's stock valued at $468,000 after buying an additional 339 shares during the period. Finally, Freestone Grove Partners LP acquired a new position in shares of Boston Scientific during the 4th quarter worth $26,702,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Trading Up 0.5%

Boston Scientific stock traded up $0.52 during mid-day trading on Thursday, hitting $108.05. 2,820,234 shares of the stock were exchanged, compared to its average volume of 7,456,434. The firm's fifty day simple moving average is $104.71 and its two-hundred day simple moving average is $102.18. The stock has a market capitalization of $160.10 billion, a price-to-earnings ratio of 64.32, a PEG ratio of 2.54 and a beta of 0.65. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 12 month low of $80.50 and a 12 month high of $108.94.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. Boston Scientific's revenue for the quarter was up 22.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on BSX shares. Needham & Company LLC reaffirmed a "buy" rating and set a $115.00 price objective on shares of Boston Scientific in a report on Wednesday, May 28th. Jefferies Financial Group reiterated a "hold" rating on shares of Boston Scientific in a research report on Monday, July 21st. Robert W. Baird increased their target price on shares of Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Erste Group Bank raised shares of Boston Scientific to a "strong-buy" rating in a research note on Thursday, May 8th. Finally, Barclays boosted their price target on shares of Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a research note on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $117.50.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of the business's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the sale, the director owned 18,479 shares in the company, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of the business's stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the sale, the director owned 2,081 shares of the company's stock, valued at $222,646.19. This trade represents a 58.23% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 174,214 shares of company stock worth $18,397,457. Company insiders own 0.50% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.